High LDL-C to HDL-C ratio linked to cardiovascular events in type 2 diabetes with retinopathy

This is a post hoc analysis of a randomized controlled trial involving 5,006 high-risk patients with type 2 diabetes and diabetic retinopathy who were receiving statins and had no prior cardiovascular disease. The study population's specific setting is not reported. The analysis examined the association between the low-density lipoprotein cholesterol (LDL-C) to high-density lipoprotein cholesterol (HDL-C) ratio (L/H ratio) and cardiovascular events. The comparator was a low L/H ratio (<2.0). The primary outcome was the risk of cardiovascular events over a median follow-up of 36.8 months.

The main result showed that a high L/H ratio was associated with a higher risk of cardiovascular events compared to a low ratio. There were 184 cardiovascular events occurred in the cohort. The effect size was a hazard ratio of 1.89, with a 95% confidence interval of 1.31-2.73 and a P-value of <0.001, indicating a statistically significant increased risk. The direction of the association was increased risk.

Key secondary outcomes are not reported in the provided data. The analysis did not report on specific secondary endpoints such as myocardial infarction, stroke, or heart failure hospitalizations.

Safety and tolerability findings are not reported. The JSON input specifies that adverse events, serious adverse events, discontinuations, and overall tolerability were not reported. Therefore, no data on the safety profile of statin therapy or the L/H ratio assessment in this context can be provided.

In comparison to prior landmark studies in diabetes and cardiovascular risk, this analysis focuses on a specific biomarker ratio in a high-risk subgroup. The practice relevance note suggests that serial L/H ratio assessment may aid risk stratification in this population. However, the analysis is observational in nature, and the causality note explicitly states that the findings are associations between the L/H ratio and cardiovascular events.

Key methodological limitations include the post hoc nature of the analysis, which can generate hypotheses but is not definitive. The study setting is not reported, limiting generalizability. The population is highly specific (high-risk type 2 diabetes with retinopathy on statins without prior CVD), which may not apply to all diabetes patients. No other limitations are reported in the JSON.

For clinical practice, these results suggest that a high L/H ratio may identify a subgroup at elevated cardiovascular risk within this specific population. The practice relevance indicates it may aid risk stratification. However, the evidence is associative, and causality cannot be inferred. Clinicians should consider this in the context of comprehensive risk assessment.

Unanswered questions remain. The causal role of the L/H ratio is not established. The optimal frequency of L/H ratio measurement for risk stratification is unknown. The generalizability to other diabetes populations or those not on statins is unclear. The impact of interventions to lower the L/H ratio on cardiovascular outcomes is not addressed.